

Patrice Cacoub

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5615279/publications.pdf>

Version: 2024-02-01

231
papers

16,769
citations

11651

70
h-index

17105

122
g-index

254
all docs

254
docs citations

254
times ranked

14666
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e30-e30.	0.9	11
2	Efficacy and safety of TNF- α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
3	Mast cells drive pathologic vascular lesions in Takayasu arteritis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 292-301.e3.	2.9	7
4	HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. <i>Journal of Hepatology</i> , 2022, 76, 174-185.	3.7	11
5	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100390.	4.9	15
6	Anti-Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema. <i>Ophthalmology</i> , 2022, 129, 520-529.	5.2	32
7	Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. <i>American Journal of Gastroenterology</i> , 2022, 117, 627-636.	0.4	9
8	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 96-96.	1.6	1
9	Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection. , 2022, 1, 393-402.		3
10	Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. <i>American Journal of Ophthalmology</i> , 2022, 238, 173-180.	3.3	13
11	Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 195-196.	0.8	7
12	Iron deficiency in heart failure patients: the French CARENFER prospective study. <i>ESC Heart Failure</i> , 2022, 9, 874-884.	3.1	22
13	Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases. <i>Nutrients</i> , 2022, 14, 1039.	4.1	11
14	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. <i>Biomedicines</i> , 2022, 10, 699.	3.2	7
15	Cerebrovascular Ischemic Events in Patients With Takayasu Arteritis. <i>Stroke</i> , 2022, 53, 1550-1557.	2.0	12
16	Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5637-5646.	2.3	7
17	Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action. <i>Journal of Internal Medicine</i> , 2022, 292, 542-556.	6.0	17
18	Vascular Behçet's disease: a comparative study from Turkey and France.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0

#	ARTICLE	IF	CITATIONS
19	Hepatitis C virus-related vasculitis. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101575.	1.5	5
20	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on "Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome" by Quartuccio et al. Joint Bone Spine. 2020;87:191-193. Joint Bone Spine, 2021, 88, 105074.	1.6	5
21	Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study. Journal of Autoimmunity, 2021, 116, 102577.	6.5	19
22	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmunity Reviews, 2021, 20, 102729.	5.8	26
23	Temporal arteritis in IgG4 related disease. Joint Bone Spine, 2021, 88, 105087.	1.6	6
24	Women and Pregnancy in Thromboangiitis Obliterans. Journal of Vascular Research, 2021, 58, 1-3.	1.4	2
25	Impact of aging on phenotype and prognosis in IgA vasculitis. Rheumatology, 2021, 60, 4245-4251.	1.9	9
26	Extrahepatic Manifestations of Hepatitis C Virus Infection. , 2021, , 21-31.		0
27	Extrahepatic Manifestations of Chronic HCV Infection. New England Journal of Medicine, 2021, 384, 1038-1052.	27.0	90
28	Direct oral anticoagulant for venous thrombosis in Behçet's syndrome. Autoimmunity Reviews, 2021, 20, 102783.	5.8	7
29	Specific Follicular Helper T Cell Signature in Takayasu Arteritis. Arthritis and Rheumatology, 2021, 73, 1233-1243.	5.6	19
30	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thrombosis and Haemostasis, 2021, 121, 982-991.	3.4	50
31	Iron deficiency in patients with cancer: a prospective cross-sectional study. BMJ Supportive and Palliative Care, 2021, , bmjspcare-2021-002913.	1.6	3
32	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie, 2021, 76, 285-295.	1.0	8
33	Spectrum and Outcome of Noninfectious Aortitis. Journal of Rheumatology, 2021, 48, 1583-1588.	2.0	4
34	Diagnosis and Management of Heart Failure in Elderly Patients from Hospital Admission to Discharge: Position Paper. Journal of Clinical Medicine, 2021, 10, 3519.	2.4	6
35	Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases. Joint Bone Spine, 2021, 88, 105226.	1.6	4
36	Gestion des péricardites aiguës récidivantes. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2021, 2021, 11-11.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
38	Rituximab-associated Vasculitis Flare: Incidence, Predictors, and Outcome. <i>Journal of Rheumatology</i> , 2020, 47, 896-902.	2.0	21
39	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2020, 15, e0240711.	2.5	54
40	Reactive oxygen species and TNF- α : the interplay between obstructive sleep apnea and Behçet's disease. <i>Sleep and Breathing</i> , 2020, 25, 1553-1554.	1.7	0
41	Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety. <i>European Journal of Internal Medicine</i> , 2020, 80, 78-85.	2.2	18
42	Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis. <i>Frontiers in Medicine</i> , 2020, 7, 594133.	2.6	8
43	Biotherapies in Uveitis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3599.	2.4	30
44	Sarcoïdose osseuse: Étude cas-témoin multicentrique. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2020, 87, 477-482.	0.0	0
45	Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. <i>Annales De Cardiologie Et D'Angéiologie</i> , 2020, 69, 158-166.	0.6	3
46	Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094261.	3.2	21
47	Pregnancy issues in Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 911-914.	3.4	12
48	Delayed acute myocarditis and COVID-19-related multisystem inflammatory syndrome. <i>ESC Heart Failure</i> , 2020, 7, 4371-4376.	3.1	46
49	P7...Rivaroxaban may trigger catastrophic antiphospholipid syndrome. , 2020, , .		1
50	Iron deficiency markers in patients undergoing iron replacement therapy: a 9-year retrospective real-world evidence study using healthcare databases. <i>Scientific Reports</i> , 2020, 10, 14983.	3.3	9
51	Cardiac sarcoidosis: A long term follow up study. <i>PLoS ONE</i> , 2020, 15, e0238391.	2.5	32
52	Correspondance on the clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrhumdis-2020-219566.	0.9	0
53	Neutrophil-Platelet and Monocyte-Platelet Aggregates in COVID-19 Patients. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1733-1735.	3.4	41
54	Strategies to prevent persistent or relapsed mixed cryoglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 137-143.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Factors influencing the recurrence of arterial involvement after surgical repair in Behçet disease. <i>Journal of Vascular Surgery</i> , 2020, 72, 1761-1769.	1.1	16
56	Risk Factors and Prevention of <i>Pneumocystis jirovecii</i> Pneumonia in Patients With Autoimmune and Inflammatory Diseases. <i>Chest</i> , 2020, 158, 2323-2332.	0.8	58
57	Cryoglobulinemia after the era of chronic hepatitis C infection. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 695-700.	3.4	23
58	Analysis of risk factors for complications and adverse obstetrical outcomes in women with Takayasu arteritis: a French retrospective study and literature review. <i>Clinical Rheumatology</i> , 2020, 39, 2707-2713.	2.2	18
59	Gastrointestinal involvement in adult IgA vasculitis (Henoch-Schönlein purpura): updated picture from a French multicentre and retrospective series of 260 cases. <i>Rheumatology</i> , 2020, 59, 3050-3057.	1.9	23
60	Acute recurrent pericarditis: from pathophysiology towards new treatment strategy. <i>Heart</i> , 2020, 106, 1046-1051.	2.9	16
61	Prognosis of large vessel involvement in large vessel vasculitis. <i>Journal of Autoimmunity</i> , 2020, 108, 102419.	6.5	17
62	Long-term safety and efficacy results in hepatitis C virus genotype 1 infected patients receiving ombitasvir/paritaprevir/ritonavir±Dasabuvir±Sofosbuvir in the TOPAZ1 and TOPAZ2 trials. <i>Journal of Viral Hepatitis</i> , 2020, 27, 497-504.	2.0	10
63	Screening coronary artery disease with computed tomography angiogram should limit normal invasive coronary angiogram, regardless of pretest probability. <i>American Heart Journal</i> , 2020, 223, 113-119.	2.7	2
64	Targeting JAK/STAT pathway in Takayasu's arteritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 951-959.	0.9	56
65	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. <i>Journal of Autoimmunity</i> , 2020, 111, 102454.	6.5	11
66	Immunomodulatory role of Interleukin-33 in large vessel vasculitis. <i>Scientific Reports</i> , 2020, 10, 6405.	3.3	11
67	Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study. <i>Frontiers in Immunology</i> , 2020, 11, 626792.	4.8	12
68	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. <i>Rheumatology</i> , 2020, 59, 3807-3816.	1.9	24
69	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020, 15, e0242306.	2.5	10
70	THU0051...LOW-DOSE INTERLEUKIN-2 SELECTIVELY EXPAND AND ACTIVATE REGULATORY T CELLS ACROSS 13 AUTOIMMUNE DISEASES.. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 237.1-238.	0.9	0
71	SAT0246...TARGETING JAK/STAT PATHWAY IN TAKAYASU'S ARTERITIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1066.1-1066.	0.9	0
72	Title is missing!. , 2020, 15, e0240711.		0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 15, e0240711.		0
74	Title is missing!. , 2020, 15, e0240711.		0
75	Title is missing!. , 2020, 15, e0240711.		0
76	Considering hepatitis C virus infection as a systemic disease. <i>Seminars in Dialysis</i> , 2019, 32, 99-107.	1.3	16
77	Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 518-526.	4.4	63
78	Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients. <i>Journal of Autoimmunity</i> , 2019, 96, 35-39.	6.5	61
79	TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses. <i>Journal of Hepatology</i> , 2019, 71, 908-919.	3.7	23
80	Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. <i>Joint Bone Spine</i> , 2019, 86, 789-793.	1.6	27
81	Using transferrin saturation as a diagnostic criterion for iron deficiency: A systematic review. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 526-532.	6.1	30
82	Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1274-1282.	0.9	96
83	Absence of HCV RNA in serum and cryoprecipitate of patients with persisting mixed cryoglobulinaemia vasculitis after direct-acting antiviral agents. <i>GastroHep</i> , 2019, 1, 134-137.	0.6	1
84	Editorial: direct-acting antivirals decrease the frequency of diabetes complications in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1094-1095.	3.7	0
85	Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 1727-1732.	5.6	51
86	Expert opinion on the use of biological therapy in non-infectious uveitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 477-490.	3.1	51
87	Corticosteroids and immunosuppressive agents for idiopathic recurrent pericarditis. <i>Autoimmunity Reviews</i> , 2019, 18, 621-626.	5.8	12
88	Cryoglobulinemia: An update in 2019. <i>Joint Bone Spine</i> , 2019, 86, 707-713.	1.6	88
89	Hepatitis C Virus Infection, a New Modifiable Cardiovascular Risk Factor. <i>Gastroenterology</i> , 2019, 156, 862-864.	1.3	12
90	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 171-172.	5.6	0

#	ARTICLE	IF	CITATIONS
91	Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 209-217.	0.9	273
92	Neuro-ophthalmological manifestations of Behçet's disease. <i>British Journal of Ophthalmology</i> , 2019, 103, 83-87.	3.9	15
93	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 811-817.	2.0	24
94	Ectopic Germinal Center-Like Structures in Minor Salivary Gland Biopsy Tissue Predict Lymphoma Occurrence in Patients With Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 1481-1488.	5.6	52
95	Large-vessel vasculitis in human immunodeficiency virus-infected patients. <i>Journal of Vascular Surgery</i> , 2018, 67, 1501-1511.	1.1	18
96	Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients. <i>American Heart Journal</i> , 2018, 198, 4-17.	2.7	49
97	Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. <i>Gut</i> , 2018, 67, 2025-2034.	12.1	104
98	Anakinra in the Treatment of Patients with Refractory Scleritis: A Pilot Study. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 915-920.	1.8	21
99	Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 123-128.	3.7	13
100	Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-low B Cells From Patients With Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2018, 70, 298-307.	5.6	24
101	Sarcoidosis with Takayasu arteritis: a model of overlapping granulomatosis. A report of seven cases and literature review. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 740-745.	1.9	20
102	Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis. <i>Antiviral Therapy</i> , 2018, 23, 1-9.	1.0	10
103	Expert Opinion on the Management of Renal Manifestations of Chronic HCV Infection. <i>Antiviral Therapy</i> , 2018, 23, 57-67.	1.0	4
104	Expert Opinion on Managing Chronic HCV in Patients with Cardiovascular Disease. <i>Antiviral Therapy</i> , 2018, 23, 35-46.	1.0	8
105	The comprehensive outcomes of hepatitis C virus infection: A multifaceted chronic disease. <i>Journal of Viral Hepatitis</i> , 2018, 25, 6-14.	2.0	23
106	Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult-onset Still disease. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 969-971.	1.2	18
107	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 11.	30.5	143
108	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. <i>Autoimmunity Reviews</i> , 2018, 17, 653-659.	5.8	40

#	ARTICLE	IF	CITATIONS
109	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	3.7	73
110	Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 288-294.	3.4	81
111	Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 152, 2052-2062.e2.	1.3	81
112	Rheumatologic Manifestations of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2017, 21, 455-464.	2.1	17
113	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
114	Ustekinumab for Behçet's disease. <i>Journal of Autoimmunity</i> , 2017, 82, 41-46.	6.5	58
115	Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era. <i>Liver International</i> , 2017, 37, 1805-1813.	3.9	26
116	Longterm Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. <i>Journal of Rheumatology</i> , 2017, 44, 1165-1172.	2.0	51
117	Cardiac sarcoidosis: Diagnosis, therapeutic management and prognostic factors. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 456-465.	1.6	35
118	Myocarditis in auto-immune or auto-inflammatory diseases. <i>Autoimmunity Reviews</i> , 2017, 16, 811-816.	5.8	52
119	Characteristics and Management of IgA Vasculitis (Henoch-Schönlein) in Adults: Data From 260 Patients Included in a French Multicenter Retrospective Survey. <i>Arthritis and Rheumatology</i> , 2017, 69, 1862-1870.	5.6	117
120	Cryoglobulinemia vasculitis: how to handle. <i>Current Opinion in Rheumatology</i> , 2017, 29, 343-347.	4.3	17
121	Comment on Nuo Solin R, et al. "Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence". <i>Infectious Diseases and Therapy</i> , 2017, 6, 297-301.	4.0	1
122	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	5.8	87
123	Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. <i>Gastroenterology</i> , 2017, 153, 49-52.e5.	1.3	125
124	The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1054-1060.	3.7	66
125	Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis. <i>JAMA Neurology</i> , 2017, 74, 1336.	9.0	76
126	HCV eradication reduces the occurrence of major adverse cardiovascular events in hepatitis C cirrhotic patients: data from the prospective ANRS CO12 CirVir cohort. <i>Journal of Hepatology</i> , 2017, 66, S20-S21.	3.7	7

#	ARTICLE	IF	CITATIONS
127	Brief Report: Defective Early B Cell Tolerance Checkpoints in Sjögren's Syndrome Patients. <i>Arthritis and Rheumatology</i> , 2017, 69, 2203-2208.	5.6	40
128	Long-Term Outcomes and Prognostic Factors of Complications in Takayasu Arteritis. <i>Circulation</i> , 2017, 136, 1114-1122.	1.6	161
129	Hepatitis C Virus Infection and Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 123-132.	1.9	21
130	New insights into HCV-related rheumatologic disorders: A review. <i>Journal of Advanced Research</i> , 2017, 8, 89-97.	9.5	24
131	Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. <i>PLoS ONE</i> , 2017, 12, e0183844.	2.5	174
132	Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. <i>Arthritis and Rheumatology</i> , 2016, 68, 1522-1530.	5.6	131
133	SAT0297â€¦Primary Sjogren Syndrome: Clinical and Biological Features According To The Presence of Anti-Ssa Antibodies from A Cohort of 176 Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 775.3-776.	0.9	0
134	Chronic hepatitis C virus infection, a new cardiovascular risk factor?. <i>Liver International</i> , 2016, 36, 621-627.	3.9	59
135	Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. <i>Journal of Hepatology</i> , 2016, 65, S82-S94.	3.7	80
136	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	5.8	87
137	THU0325â€¦Long-Term Outcome of Patients with Primary Antiphospholipid Syndrome: A Retrospective Multicenter Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 305.1-305.	0.9	1
138	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Therapeutic Advances in Infectious Disease</i> , 2016, 3, 3-14.	1.8	176
139	Systemic sclerosis: An update in 2016. <i>Autoimmunity Reviews</i> , 2016, 15, 417-426.	5.8	126
140	Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1777-1782.	0.9	136
141	Iron deficiency anaemia. <i>Lancet, The</i> , 2016, 387, 907-916.	13.7	960
142	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	2.5	19
143	Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. <i>PLoS ONE</i> , 2016, 11, e0162965.	2.5	27
144	IFN-Î± induces IL-10 production and tilt the balance between Th1 and Th17 in Behçet disease. <i>Autoimmunity Reviews</i> , 2015, 14, 370-375.	5.8	50

#	ARTICLE	IF	CITATIONS
145	Interaction between diabetes and a high ankle-brachial index on mortality risk. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 615-621.	1.8	18
146	Th1 and Th17 Cytokines Drive Inflammation in Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1353-1360.	5.6	195
147	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC13 lymphoC study. <i>American Journal of Hematology</i> , 2015, 90, 197-203.	4.1	84
148	P0813 : All oral therapy (Sofosbuvir-Ribavirin) combination in severe HCV-mixed cryoglobulinemia vasculitis, the vasculidic study. <i>Journal of Hepatology</i> , 2015, 62, S640.	3.7	4
149	Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. <i>Journal of Autoimmunity</i> , 2015, 62, 67-74.	6.5	178
150	Extrahepatic manifestations in chronic hepatitis C virus carriers. <i>Lupus</i> , 2015, 24, 469-482.	1.6	46
151	Cryoglobulinemia Vasculitis. <i>American Journal of Medicine</i> , 2015, 128, 950-955.	1.5	229
152	Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. <i>RMD Open</i> , 2015, 1, e000034.	3.8	60
153	Burden of HIV and hepatitis C infection: the changing epidemiology of hepatitis C in HIV-infected patients in France. <i>Liver International</i> , 2015, 35, 65-70.	3.9	26
154	Takayasu Arteritis and Pregnancy. <i>Arthritis and Rheumatology</i> , 2015, 67, 3262-3269.	5.6	65
155	Non HCV-related infectious cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey and systematic review of the literature. <i>Journal of Autoimmunity</i> , 2015, 65, 74-81.	6.5	76
156	Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 1585-1594.	4.7	215
157	PegIFN±/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. <i>Journal of Hepatology</i> , 2015, 62, 24-30.	3.7	86
158	Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 509-15.	0.8	18
159	Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers. <i>Toxicologic Pathology</i> , 2014, 42, 658-671.	1.8	13
160	CD21 ^{low} Marginal Zone B Cells Highly Express Fc Receptor-like 5 Protein and Are Killed by Anti-Fc Receptor-like 5 Immunotoxins in Hepatitis C Virus-Associated Mixed Cryoglobulinemia Vasculitis. <i>Arthritis and Rheumatology</i> , 2014, 66, 433-443.	5.6	16
161	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2014, 46, S165-S173.	0.9	218
162	Behçet's disease in budd-chiari syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 104.	2.7	57

#	ARTICLE	IF	CITATIONS
163	Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. <i>Autoimmunity Reviews</i> , 2014, 13, 319-326.	5.8	20
164	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	1.3	232
165	Findings of Cardiac Magnetic Resonance Imaging in Asymptomatic Myocardial Ischemic Disease in Takayasu Arteritis. <i>American Journal of Cardiology</i> , 2014, 113, 881-887.	1.6	30
166	Autoimmune diseases in HIV-infected patients: 52 cases and literature review. <i>Autoimmunity Reviews</i> , 2014, 13, 850-857.	5.8	101
167	Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey. <i>Autoimmunity Reviews</i> , 2014, 13, 630-634.	5.8	23
168	Current and future therapeutic strategies for treating mixed cryoglobulinemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 381-390.	0.8	1
169	Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. <i>Genes and Immunity</i> , 2014, 15, 500-505.	4.1	55
170	Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. <i>Osteoporosis International</i> , 2013, 24, 1751-1757.	3.1	30
171	Using Rituximab Plus Fludarabine and Cyclophosphamide as a Treatment for Refractory Mixed Cryoglobulinemia Associated With Lymphoma. <i>Arthritis Care and Research</i> , 2013, 65, 643-647.	3.4	34
172	Small vessel involvement in Takayasu's arteritis. <i>Autoimmunity Reviews</i> , 2013, 12, 355-362.	5.8	41
173	Hepatitis C Virus Infection, Mixed Cryoglobulinemia, and Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2013, 61, 623-637.	1.9	124
174	Presentation and Prognosis of Cardiac Involvement in Hepatitis C Virus-Related Vasculitis. <i>American Journal of Cardiology</i> , 2013, 111, 265-272.	1.6	43
175	Renal involvement in HCV-related vasculitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 334-339.	1.5	26
176	Expansion of Autoreactive Unresponsive CD21 ^{low} B Cells in Sjögren's Syndrome Associated Lymphoproliferation. <i>Arthritis and Rheumatism</i> , 2013, 65, 1085-1096.	6.7	176
177	Cryoglobulinemia vasculitis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 10-18.	4.3	95
178	Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune-Mediated Inflammatory Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 1504-1514.	3.4	43
179	Prevalence, characteristics and prognostic significance of anemia in daily practice. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 345-354.	0.5	17
180	Spectrum of Cardiac Lesions in Behçet Disease. <i>Medicine (United States)</i> , 2012, 91, 25-34.	1.0	199

#	ARTICLE	IF	CITATIONS
181	Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Blood</i> , 2012, 119, 5996-6004.	1.4	175
182	Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. <i>Journal of Hepatology</i> , 2012, 56, 455-463.	3.7	135
183	The DRESS Syndrome: A Literature Review. <i>American Journal of Medicine</i> , 2011, 124, 588-597.	1.5	788
184	Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. <i>Autoimmunity Reviews</i> , 2011, 11, 48-55.	5.8	158
185	Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 1748-1757.	6.7	95
186	Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. <i>New England Journal of Medicine</i> , 2011, 365, 2067-2077.	27.0	683
187	Peripheral Neuropathies Associated With Primary Sjögren Syndrome. <i>Medicine (United States)</i> , 2011, 90, 133-138.	1.0	94
188	Expansion of Functionally Anergic CD21 ^{low} Marginal Zone-like B Cell Clones in Hepatitis C Virus Infection-Related Autoimmunity. <i>Journal of Immunology</i> , 2011, 187, 6550-6563.	0.8	89
189	Takayasu Arteritis in France. <i>Medicine (United States)</i> , 2010, 89, 1-17.	1.0	138
190	Rituximab plus Peg-interferon- α /ribavirin compared with Peg-interferon- α /ribavirin in hepatitis C-related mixed cryoglobulinemia. <i>Blood</i> , 2010, 116, 326-334.	1.4	248
191	Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: Data from the French Autoimmunity and Rituximab registry. <i>Arthritis Care and Research</i> , 2010, 62, 1787-1795.	3.4	97
192	Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients. <i>Gut</i> , 2010, 59, 1709-1715.	12.1	28
193	Causes and Predictive Factors of Mortality in a Cohort of Patients with Hepatitis C Virus-related Cryoglobulinemic Vasculitis Treated with Antiviral Therapy. <i>Journal of Rheumatology</i> , 2010, 37, 615-621.	2.0	61
194	Manifestations of Chronic Hepatitis C Virus Infection Beyond the Liver. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 1017-1029.	4.4	147
195	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. <i>Journal of Hepatology</i> , 2010, 53, 1006-1012.	3.7	46
196	The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 337-344.	0.9	44
197	Rituximab may form a complex with IgM mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. <i>Arthritis and Rheumatism</i> , 2009, 60, 3848-3855.	6.7	129
198	Hepatitis B-Related Autoimmune Manifestations. <i>Rheumatic Disease Clinics of North America</i> , 2009, 35, 125-137.	1.9	76

#	ARTICLE	IF	CITATIONS
199	Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. <i>Antiviral Therapy</i> , 2009, 14, 839-845.	1.0	25
200	Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. <i>Arthritis and Rheumatism</i> , 2008, 58, 604-611.	6.7	115
201	Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2897-2907.	6.7	37
202	Antiphospholipid antibodies, antiphospholipid syndrome and infections. <i>Autoimmunity Reviews</i> , 2008, 7, 272-277.	5.8	161
203	REACH: International prospective observational registry in patients at risk of atherothrombotic events Results for the French arm at baseline and one year. <i>Archives of Cardiovascular Diseases</i> , 2008, 101, 81-88.	1.6	31
204	Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1431-1436.	0.9	126
205	Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 23-28.	4.3	91
206	Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: A prospective, real-life, observational study. <i>World Journal of Gastroenterology</i> , 2008, 14, 6195.	3.3	34
207	Hepatitis C virus-associated B-cell proliferation—the role of serum B lymphocyte stimulator (BlyS/BAFF). <i>Rheumatology</i> , 2007, 46, 65-69.	1.9	98
208	Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 283-287.	0.9	147
209	Role of matrix metalloproteinases, proinflammatory cytokines, and oxidative stress-derived molecules in hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. <i>Arthritis and Rheumatism</i> , 2007, 56, 1315-1324.	6.7	28
210	Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study. <i>Arthritis and Rheumatism</i> , 2006, 54, 3696-3706.	6.7	227
211	Increased Risks of Lymphoma and Death Among Patients With Non-Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>Archives of Internal Medicine</i> , 2006, 166, 2101.	3.8	131
212	Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?. <i>Blood</i> , 2005, 105, 74-76.	1.4	200
213	Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. <i>Arthritis and Rheumatism</i> , 2005, 52, 2917-2925.	6.7	76
214	Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. <i>American Journal of Kidney Diseases</i> , 2004, 43, 617-623.	1.9	171
215	Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 2004, 50, 3668-3678.	6.7	104
216	Predominance of type 1 (Th1) cytokine production in the liver of patients with HCV-associated mixed cryoglobulinemia vasculitis. <i>Journal of Hepatology</i> , 2004, 41, 1031-1037.	3.7	47

#	ARTICLE	IF	CITATIONS
217	CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. <i>Blood</i> , 2004, 103, 3428-3430.	1.4	207
218	Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. <i>Journal of Rheumatology</i> , 2004, 31, 2199-206.	2.0	90
219	Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 36, 812-818.	3.7	98
220	Regression of Splenic Lymphoma with Villous Lymphocytes after Treatment of Hepatitis C Virus Infection. <i>New England Journal of Medicine</i> , 2002, 347, 89-94.	27.0	760
221	Plasma Exchange and Interferon-Alpha Pharmacokinetics in Patients with Hepatitis C Virus-Associated Systemic Vasculitis. <i>Nephron</i> , 2002, 91, 627-630.	1.8	28
222	Interferon-? and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. <i>Arthritis and Rheumatism</i> , 2002, 46, 3317-3326.	6.7	171
223	Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. <i>Arthritis and Rheumatism</i> , 2001, 44, 2118-2124.	6.7	78
224	Extrahepatic Manifestations Associated with Hepatitis C Virus Infection: A Prospective Multicenter Study of 321 Patients. <i>Medicine (United States)</i> , 2000, 79, 47-56.	1.0	483
225	Extrahepatic manifestations of chronic hepatitis C. <i>Arthritis and Rheumatism</i> , 1999, 42, 2204-2212.	6.7	560
226	Mixed cryoglobulinemia and hepatitis C virus. <i>American Journal of Medicine</i> , 1994, 96, 124-132.	1.5	226
227	HEPATITIS C VIRUS AND ESSENTIAL MIXED CRYOGLOBULINAEMIA. <i>Rheumatology</i> , 1993, 32, 689-692.	1.9	37
228	Results of subtotal pericardiectomy for constrictive pericarditis. <i>European Journal of Cardio-thoracic Surgery</i> , 1993, 7, 252-256.	1.4	70
229	Characterization of Cryoglobulins by Immunoblotting. <i>Clinical Chemistry</i> , 1992, 38, 798-802.	3.2	194
230	Vascular Behçet's disease: a comparative study from Turkey and France. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1
231	Antiphospholipid syndrome: the burden of inadequate anticoagulation management. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	1